How are oligo therapeutics revolutionising genetic disease treatments through precise targeting and transformative therapies? In this article, we explore how they provide precise gene expression interference for untreatable conditions by directly targeting disease-associated proteins and genetic mutations.

As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape.

The Sustainable Healthcare Coalition (SHC) emphasises the importance of collaboration with industry to address climate change in healthcare.

A program to reduce the waste of medicines and waste from medicines, centred around six pillars for sustainable pharma.

John Lopez of Novartis discusses the more sustainable possibilities refractive index monitoring offers in SPPS and SPOS.

Key opinion leaders discuss techniques for peptide characterisation and the challenges posed by increasing regulatory requirements.

Novo Nordisk has implemented recombinant peptide production techniques with chemical and enzymatic transformations to reduce its carbon footprint in insulin production, as explained by Thomas Høeg-Jensen, Scientific Director at Novo Nordisk.

Key opinion leaders explore recent developments for bispecific antibodies, from new delivery technologies to the complexity of their pharmacokinetic profiles.

Nexelis discussed the preclinical stage of vaccine development at Vaccines EU 2022, highlighting that the choices made during this stage will impact the rest of the development process.

We gain a glimpse into what the landscape of antisense oligonucleotides looks like today, from computational representations to protein purification.

Opinion leaders from Merck and AbbVie discuss how antibody-based molecular engineering is developing with new AI/ML technologies.

The peptide market is continually developing, but how are manufacturers responding to its new requirements and altering the landscape of peptide manufacturing?

November’s webinar, Adaptive Laboratory Environment: Collaboration Across our Development Teams Produces Optimal Clinical Assay, discusses Nexelis’s process in recombinant protein production, optimisation, and characterisation.

Experts from King’s College London, Janssen, and Merck Sharp & Dohme congregate to talk the future of optimised vaccine manufacturing.

During the pandemic, a layperson couldn't avoid learning about vaccinations. But as the world returns to “normal”, how does this new-found focus on vaccines manifest for regulators, producers, prescribers, and the public? 

Mark Doherty, Senior Medical Manager at GSK, leads a Discussion Group on leveraging the mechanisms of action in therapeutic vaccine development.

Galahad Deperalta, Senior Scientist and Innovation Group Leader at Genentech, leads a Discussion Group on the next generation of biotherapeutic development.

Discover the top bioanalysis presentations from Biologics UK 2022.